期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 29, 期 25, 页码 3381-3388出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2010.34.3426
关键词
-
类别
资金
- sanofi-aventis
- Bayer Pharmaceuticals
- Novartis
- University of Wisconsin (UW) Department of Family Medicine Primary Care
- Health Resources and Services Administration National Research Service [T32HP10010]
- UW Carbone Cancer Center
- National Cancer Institute-National Institutes of Health (NIH) [P30CA014520-34]
- UW Institute for Clinical and Translational Research
- National Center for Research Resources-NIH [1UL1RR025011]
- Wisconsin Partnership Program
- UW
Purpose Adjuvant chemotherapy is typically considered for patients with stage II colon cancer characterized by poor prognostic features, including obstruction, perforation, emergent admission, T4 stage, resection of fewer than 12 lymph nodes, and poor histology. Despite frequent use, the survival advantage conferred on patients with stage II disease by chemotherapy is yet unproven. We sought to determine the overall survival benefit of chemotherapy among patients with stage II colon cancer having poor prognostic features. Patients and Methods A total of 43,032 Medicare beneficiaries who underwent colectomy for stage II and III primary colon adenocarcinoma diagnosed from 1992 to 2005 were identified from the Surveillance, Epidemiology, and End Results (SEER) -Medicare database. chi(2) and two-way analysis of variance were used to assess differences in patient-and disease-related characteristics. Five-year overall survival was examined using Kaplan-Meier survival analysis and Cox proportional hazards regression with propensity score weighting. Results Of the 24,847 patients with stage II cancer, 75% had one or more poor prognostic features. Adjuvant chemotherapy was received by 20% of patients with stage II disease and 57% of patients with stage III disease. After adjustment, 5-year survival benefit from chemotherapy was observed only for patients with stage III disease (hazard ratio[HR], 0.64; 95% CI, 0.60 to 0.67). No survival benefit was observed for patients with stage II cancer with no poor prognostic features (HR, 1.02; 95% CI, 0.84 to 1.25) or stage II cancer with any poor prognostic features (HR, 1.03; 95% CI, 0.94 to 1.13). Conclusion Among Medicare patients identified with stage II colon cancer, either with or without poor prognostic features, adjuvant chemotherapy did not substantially improve overall survival. This lack of benefit must be considered in treatment decisions for similar older adults with colon cancer. J Clin Oncol 29:3381-3388. (C) 2011 by American Society of Clinical Oncology
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据